Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.
about
Postoperative adjuvant chemotherapy in rectal cancer operated for cureAdjuvant chemotherapy for rectal cancer: Is it needed?Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancerAdjuvant chemotherapyMeta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.The role of capecitabine in locally advanced rectal cancer treatment: an update.Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiationCould preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatmentConsensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014Neoadjuvant treatment in rectal cancer: actual status.Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancerBevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.Is It Possible to Shorten the Duration of Adjuvant Chemotherapy for Locally Advanced Rectal Cancer?Clinical information available to oncologists in surgically treated rectal cancer: room to improve.Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patientsSelective use of adjuvant chemotherapy for rectal cancer patients with ypN0.Locally advanced rectal cancer: a comparison of management strategies.Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013.Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.The multidisciplinary approach to the treatment of rectal cancer: 2015 update.Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients?Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.Update on advances and controversy in rectal cancer treatment.Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study.Progress in rectal cancer treatment.Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery.Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study.Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.A population-based study elicits a reverse correlation between age and overall survival in elderly patients with rectal carcinoma receiving adjuvant chemotherapy.Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer.T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.Oncologic results and prognostic predictors of patients with locally advanced rectal cancer showing ypN0 after radical surgery following neoadjuvant chemoradiotherapy.Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome.
P2860
Q24201072-43D59257-1395-4FB3-9195-CF1227AE1973Q26775099-84CD72C2-881C-4F6A-BA43-6299B6B1ACC7Q27003878-65762DA4-4B0B-4CDB-94A4-886BF69A540DQ33698724-FA93CE76-F00C-4AB8-9E98-A7A3BFA14F96Q33798353-76032EA0-ACA9-4075-B947-0DDA96AE150BQ34276823-D51BF00D-12B9-4BE5-96D9-ACE9AAE9C498Q34499179-D2975C90-154B-4858-918E-B3D74943ABC8Q34719568-A0F4EFD3-670F-460E-8709-D781F534F858Q35183525-629CB845-B863-4C4F-A3BF-04317BA4A2EAQ35445092-692F0EB6-61B7-4692-90F2-CCFC5718B92BQ35687452-B719A566-E00D-4BAE-8153-FC4F20BC1AC9Q35758360-130EF13D-4FA2-430D-9284-A5CC1151D394Q35817933-841329DC-D65F-4379-A254-F9204A807201Q35920508-B5E8D339-EDE9-4A2C-B5B6-22785106F9A6Q36838083-E6C64D66-95F5-4D10-A95D-047FACB7AAE1Q36897763-9150414F-F140-47C2-9AC9-6AB8A9971920Q37119089-5E650E34-ABC5-441E-856B-D787FCF57E2CQ37663255-5A3AEFB0-8535-4896-B260-0AB396F1C2CDQ37895253-27E34C62-7FD4-493D-9CD2-8C051B678694Q37962660-A09ADF3B-A31A-4D0B-859C-42EFDEFDEC20Q38136565-AC01405A-1A0C-41C2-A356-86B02EBF66B7Q38208009-EE9D760F-B092-4B5E-BDC6-C5BF702ABF64Q38216007-50FE38EE-C3E9-4B2E-8A07-060571883170Q38272299-9DD9E975-487A-4594-900A-32B1F3898F95Q38285536-951444E9-B90E-4DB7-887F-B855C71CC119Q38432466-56763E62-BD46-4D99-ADA8-E38EADBEEA71Q38692803-7EB7E976-458A-4934-B2D1-32514D42E640Q38973703-8996AE8D-8EDB-40D8-835A-51446F208B85Q39554319-4D810614-1F4E-41E4-BE81-253BA09BC699Q40171741-ACD4E0E5-D4A5-4246-ABD1-58EDD2AF51E8Q40783676-C580BAA4-36AF-4E39-AFE8-ACCA5F0A95EDQ41594853-BE096139-27DF-40E7-A982-70D74C5B5E79Q41743411-083EF81B-648D-44E2-857D-6483878827A0Q42794358-9150A79A-54FC-4ACD-87BF-7642638354F0Q43775916-A3C30F6E-0471-4B0F-9DDD-1A29334FDFA9Q44412713-947722E4-3F2E-48FF-9ECB-94100C226E15Q44453359-C0FC279E-57A6-4DE1-9359-D824DB726A01Q47128089-757CEC9A-78C4-4FE3-93FD-156B4A811D80Q50973557-B8CB8D34-EE72-4B2D-89ED-FE842FEC0E3FQ53137607-A9464341-4084-4DE4-ADC6-E81388611EC0
P2860
Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@en
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@nl
type
label
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@en
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@nl
prefLabel
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@en
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@nl
P2093
P2860
P921
P356
P1433
P1476
Does adjuvant fluoropyrimidine ...... c review of randomised trials.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDQ054
P577
2010-03-15T00:00:00Z